Retour à la liste des essais cliniquesCancers urogénitaux

PEACE 7

A randomised Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localised prostate cancer and high-risk features of relapse, from the Prostate Cancer Consortium in Europe (PEACE).

Ouvert à Paris depuis le : 21/07/2025
Ouvert à Saint-Cloud depuis le : 08/10/2025
Public cible : Adult
Phase : Phase III

Description de l'essai

Primary endpoint (estimated):;Metastasis-free survival (MFS) À time from randomization to detection of metastasis or death.;Secondary endpoints (estimated):;Progression-free survival (PFS), clinical or biochemical;Overall survival (OS);Safety/tolerability and adverse events;Quality of life assessments;Time to next systemic therapy or symptomatic skeletal events

Url of the trial

Investigateurs principaux

GILLES CREHANGE

Professeur - Médecin

Contacter

PIERRE GRAFF CAILLEAUD

Médecin

Contacter